Sugi Predict

Sugi Predict / Compounds / SCHEMBL14150613

SCHEMBL14150613

SCHEMBL14150613

N[C@@H](CSSC[C@H](N)C(=O)Oc1ccccc1)C(=O)Oc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ KIF11 P52732 7/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ SLC1A3 P43003 1/20 0.41
▸ ELANE P08246 1/20 0.40
▸ ALPI P09923 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ PTGS1 P23219 1/20 0.39
▸ XIAP P98170 1/20 0.39
▸ SLC7A5 Q01650 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ METAP2 P50579 2/20 0.38
▸ METAP1 P53582 2/20 0.38
▸ SLC1A5 Q15758 1/20 0.37
▸ ALOX15 P16050 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14150614 1.00 ATM (0.44) ATML3MBTL1KIF11TDP1SLC1A3
SCHEMBL14227031 1.00 ATM (0.44) ATML3MBTL1KIF11TDP1SLC1A3
SCHEMBL14227105 0.92 KIF11 (0.53) ATML3MBTL1KIF11SLC1A3ELANE
SCHEMBL16351388 0.92 KIF11 (0.53) ATML3MBTL1KIF11SLC1A3ELANE
SCHEMBL14227086 0.91 ATM (0.44) ATML3MBTL1KIF11TDP1SLC1A3
SCHEMBL16086931 0.85 ATM (0.46) ATML3MBTL1KIF11TDP1SLC1A3
SCHEMBL2564139 0.85 ATM (0.46) ATML3MBTL1KIF11TDP1SLC1A3
Water SCHEMBL10790799 0.84 ATM (0.45) ATML3MBTL1KIF11TDP1SLC1A3
SCHEMBL12229245 0.83 LMNA (0.47) L3MBTL1KIF11ELANEHPGD
SCHEMBL24530374 0.81 ATM (0.46) ATML3MBTL1TDP1SLC1A3ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759748-B2 Compounds as L-cystine crystallization inhibitors and uses thereof NEW YORK UNIVERSITY (US) 2020-09-01 — — US disclosed
US-10759748-B2 Compounds as L-cystine crystallization inhibitors and uses thereof NEW YORK UNIVERSITY (US) 2020-09-01 — — US disclosed
US-20180305307-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2018-10-25 — — US disclosed
US-20150099806-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2015-04-09 — — US disclosed
US-20150099806-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2015-04-09 — — US disclosed
US-20150099806-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2015-04-09 — — US disclosed
US-8916609-B2 Compounds as L-cystine crystallization inhibitors and uses thereof NEW YORK UNIVERSITY (US) 2014-12-23 — — US disclosed
US-8916609-B2 Compounds as L-cystine crystallization inhibitors and uses thereof NEW YORK UNIVERSITY (US) 2014-12-23 — — US disclosed
US-8916609-B2 Compounds as L-cystine crystallization inhibitors and uses thereof NEW YORK UNIVERSITY (US) 2014-12-23 — — US disclosed
US-20120316236-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2012-12-13 — — US disclosed
US-20120316236-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2012-12-13 — — US disclosed
US-20120316236-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF NEW YORK UNIVERSITY 2012-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099806-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF ATP6V1B1, GLS, REN ATM 3176/4885L3MBTL1 346/4885KIF11 4357/4885
US-10759748-B2 Compounds as L-cystine crystallization inhibitors and uses thereof ATP6V1B1, GLS, REN ATM 3176/4885L3MBTL1 346/4885KIF11 4357/4885
US-20180305307-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF ATP6V1B1, GLS, REN ATM 3111/4885L3MBTL1 310/4885KIF11 4387/4885
US-20120316236-A1 COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF ATP6V1B1, GLS, REN ATM 3176/4885L3MBTL1 346/4885KIF11 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.